Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Director Stephen M. Dow acquired 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 18th. The shares were purchased at an average cost of $10.00 per share, for a total transaction of $250,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) traded down 2.53% during midday trading on Tuesday, hitting $11.55. The stock had a trading volume of 1,653,457 shares. Alder BioPharmaceuticals, Inc. has a 52-week low of $10.05 and a 52-week high of $36.48. The company’s market cap is $582.24 million. The company’s 50 day moving average is $17.14 and its 200 day moving average is $20.51.

Alder BioPharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported ($1.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by $1.04. During the same period in the prior year, the company earned ($0.76) earnings per share. On average, analysts anticipate that Alder BioPharmaceuticals, Inc. will post ($6.27) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Stephen M. Dow Buys 25,000 Shares of Alder BioPharmaceuticals, Inc. (ALDR) Stock” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/07/18/stephen-m-dow-buys-25000-shares-of-alder-biopharmaceuticals-inc-aldr-stock.html.

ALDR has been the topic of a number of analyst reports. Zacks Investment Research raised Alder BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Tuesday, July 11th. Credit Suisse Group cut Alder BioPharmaceuticals from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $30.00 to $17.00 in a research note on Wednesday, June 28th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $43.00 price target on shares of Alder BioPharmaceuticals in a research note on Thursday, March 30th. Needham & Company LLC initiated coverage on Alder BioPharmaceuticals in a research note on Monday, May 15th. They issued a “buy” rating and a $36.00 price target on the stock. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and issued a $51.00 price target on shares of Alder BioPharmaceuticals in a research note on Wednesday, June 28th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $35.00.

A number of hedge funds and other institutional investors have recently made changes to their positions in ALDR. Bank of Montreal Can boosted its position in shares of Alder BioPharmaceuticals by 3,047.2% in the first quarter. Bank of Montreal Can now owns 5,602 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 5,424 shares during the period. Stifel Financial Corp bought a new stake in shares of Alder BioPharmaceuticals during the first quarter valued at about $206,000. Trexquant Investment LP bought a new stake in shares of Alder BioPharmaceuticals during the first quarter valued at about $265,000. Russell Investments Group Ltd. bought a new stake in shares of Alder BioPharmaceuticals during the fourth quarter valued at about $334,000. Finally, Baird Financial Group Inc. boosted its stake in shares of Alder BioPharmaceuticals by 7.9% in the first quarter. Baird Financial Group Inc. now owns 18,441 shares of the biopharmaceutical company’s stock valued at $384,000 after buying an additional 1,349 shares during the period.

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Insider Buying and Selling by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.